Abstract Details

Title Impact of Zero Seizures on Healthcare Resource Utilization Among Cenobamate Patients

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P1 - Poster Session 1 (8:00 AM-9:00 AM)

Poster/Presentation
Number 11-010

Objective To evaluate the impact of 90-day and 360-day zero-seizure intervals on inpatient (IP) and emergency room (ER) encounters) retrospectively.

Background Patients with uncontrolled seizures are burdened by decreased overall health and quality-of-life and utilize more healthcare resources.

Design/Methods De-identified electronic health records from the Truveta database identified adults (≥18 years) who initiated cenobamate between 1/1/2020-4/12/2025. Patients were included if they had any encounter (office visit, IP, ER; including non-epilepsy related) ≥180 days before initiating cenobamate and had any type of medication dispensed or requested in the ≥360 days before initiation. Depending on the zero-seizure interval that was measured, patients were required to have at least one seizure observation-related encounter at least 90 or 360 days post-completion of a 90-day enrollment period. Zero-seizure status was calculated by taking the difference in time between the last available encounter date (regardless of ongoing cenobamate use) where seizures were measured (seizures could be ≥0) and the last date of an observed seizure (seizures must be >0). If those time differences were ≥90 or ≥360 days, this was transformed into a binary variable. The frequency of all-cause and epilepsy-related IP and ER encounters for the subsequent follow-up period, up to 360 days, were summed and transformed into annual rates.

Results 669 and 361 patients were included in the 90-day and the 360-day zero seizures analyses, respectively. All subsequent all-cause and epilepsy-related IP and ER rates were significantly reduced for patients with 90-day zero-seizure intervals (ranging from 36% for all-cause ER to 78% for epilepsy-related ER) and 360-day zero-seizure intervals (ranging from 67% for all cause ER to 94% for epilepsy-related IP) vs those without a 90- or 360-day zero-seizure interval.

Conclusions

Among patients initiating cenobamate, there was a potential healthcare resource utilization benefit during the subsequent 360-day period after achieving zero seizures for 90 or 360 days.

Authors/Disclosures
Arkady Nisman, PharmD (SK Life Science, Inc.) PRESENTER	Dr. Nisman has received personal compensation for serving as an employee of SK Life Science, Inc.. Dr. Nisman has a non-compensated relationship as a Senior Director, Medical Affairs with SK Life Science, Inc. that is relevant to AAN interests or activities.
Sean Stern (SK life science)	Mr. Stern has received personal compensation for serving as an employee of SK Life Science.
Louis Ferrari (SK Lifescience)	Louis Ferrari has received personal compensation for serving as an employee of SK Life science.

��ɫ��

��ɫ��